Fertilo In Vitro Research Study and Trial

Eligibility Criteria

• 1. Written informed consent.
• 2. Premenopausal, Age 18-35.
• 3. Body mass index (BMI) 21-40.
• 4. Candidate for IVF according to the ASRM definition (infertile for ≥12 months, require the use of donor sperm, or the inability to achieve a successful pregnancy based on a patient's medical, sexual, and reproductive history, age, physical findings, diagnostic testing, or any combination of those factors).
• 5. No contraindications to the use of oral contraceptive pills (OCP) or gonadotropins.
• 6. Plan to use embryos for transfer within 2 months of blastocyst cryopreservation.
• 7. Anti-mullerian hormone (AMH) ≥ 3 ng/mL within 6 months of Screening/Visit 1 or assessed at the screening visit.
• 8. Normal uterine cavity as assessed by hysteroscopy, hysterosalpingography or sonohysterography within 12 months of Screening/Visit 1 or assessed at the screening visit.
• 9. Having adequate visualization of both ovaries, without evidence of significant abnormality/pathology or major cyst documented by transvaginal ultrasound within 3 months of screening or assessed during screening period.
• 10. No endometriosis of American Fertility Society (AFS) grade 3 or 4 or presence of endometrioma.
• 11. Minimum of 1 month without treatment with either clomiphene citrate, GnRH agonist or gonadotropins prior to start of ovarian stimulation.
• 12. Have a male partner with semen analysis within the past 12 months prior to randomization considered adequate to proceed with intracytoplasmic sperm injection (ICSI) according to the center's standard practice. If this criterion is not met, the subject can only be entered if donor sperm will be used.
• 1. History of recurrent pregnancy loss (defined as \>2 clinical pregnancies without live birth).
• 2. Baseline prolactin levels greater than 30 ng/ml
• 3. Male: requirement for retrograde ejaculation procedures or surgical sperm retrievals.
• 4. Any clinically relevant pathology that in the judgment of the investigator could impair embryo implantation or pregnancy continuation.
• 5. Use of preimplantation genetic testing (PGT) of oocytes, embryos, or transferred blastocysts during participation in the study.
• 6. Use of donated oocytes, embryos or blastocysts for this treatment cycle while participating in the study or use of oocytes, embryos, or blastocysts from a previous treatment cycle.
• 7. Participation in a concurrent clinical trial or in another investigational drug trial within the past 2 months.